Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Key Points

• JPMorgan raised Jazz Pharmaceuticals’ price target to $310 from $300 and maintained an “overweight” rating, implying roughly 34% upside. The broader analyst consensus is “Moderate Buy,” with an average target of $293.45.
• Jazz’s third-quarter revenue rose 10.4% year over year to $1.24 billion, beating estimates, while its per-share loss was narrower than expected. Management also increased 2026 revenue guidance to approximately $4.78 billion-$4.90 billion.
• Shares climbed 7.7% to $230.94, supported by product growth and pipeline catalysts including Xywav, Ziihera and the Actio acquisition. However, the company reported a quarterly loss versus a profit a year earlier, and insiders have sold shares under pre-arranged trading plans.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) had its target price upped by analysts at JPMorgan Chase & Co. from $300.00 to $310.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an "overweight" rating on the specialty pharmaceutical company's stock. JPMorgan Chase & Co.'s price objective points to a potential upside of 34.23% from the stock's current price.

A number of other analysts have also weighed in on JAZZ. UBS Group increased their target price on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a "buy" rating in a research note on Friday, September 11th. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the stock a "buy" rating in a report on Wednesday, October 7th. TD Cowen boosted their price objective on shares of Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. Needham & Company LLC upped their target price on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a "buy" rating in a research note on Wednesday, August 26th. Finally, Wells Fargo & Company increased their price objective on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $293.45.

Jazz Pharmaceuticals Trading Up 7.7%

Shares of JAZZ traded up $16.50 during midday trading on Tuesday, hitting $230.94. The stock had a trading volume of 783,904 shares, compared to its average volume of 930,050. The stock's 50 day moving average is $231.16 and its 200 day moving average is $216.50. The firm has a market cap of $14.99 billion, a PE ratio of 15.96, a price-to-earnings-growth ratio of 0.41 and a beta of 0.38. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58. Jazz Pharmaceuticals has a 1 year low of $128.80 and a 1 year high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating the consensus estimate of ($4.05) by $0.17. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.21 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The firm's revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.13 EPS. As a group, analysts forecast that Jazz Pharmaceuticals will post 10.87 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Bruce C. Cozadd sold 6,000 shares of the company's stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $230.33, for a total transaction of $1,381,980.00. Following the transaction, the director directly owned 345,875 shares of the company's stock, valued at approximately $79,665,388.75. This represents a 1.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the firm's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the sale, the executive vice president directly owned 65,686 shares of the company's stock, valued at approximately $16,401,794.20. This represents a 53.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 94,121 shares of company stock valued at $23,337,922. Company insiders own 4.10% of the company's stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in JAZZ. Pictet Asset Management Holding SA boosted its holdings in Jazz Pharmaceuticals by 1.0% during the 3rd quarter. Pictet Asset Management Holding SA now owns 149,115 shares of the specialty pharmaceutical company's stock valued at $34,640,000 after acquiring an additional 1,516 shares during the period. Pegasus Asset Management Inc. acquired a new stake in shares of Jazz Pharmaceuticals during the third quarter worth about $3,664,000. AlphaCentric Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 29.8% during the third quarter. AlphaCentric Advisors LLC now owns 4,688 shares of the specialty pharmaceutical company's stock worth $1,085,000 after purchasing an additional 1,075 shares in the last quarter. International Assets Investment Management LLC purchased a new position in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $225,000. Finally, Calamos Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 764.2% in the third quarter. Calamos Advisors LLC now owns 12,366 shares of the specialty pharmaceutical company's stock valued at $2,863,000 after purchasing an additional 10,935 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q3 results beat expectations: Jazz reported revenue of approximately $1.24 billion, up 10.4% year over year and above the $1.21 billion consensus estimate. Its adjusted loss of $3.88 per share was narrower than the expected $4.05 loss. Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Full-year outlook increased: Management raised 2026 revenue guidance to roughly $4.78 billion-$4.90 billion, above Wall Street expectations of about $4.7 billion. Growth is being supported by oncology products and rare-sleep medicines, including 12% year-over-year Xywav revenue growth and 425 net patient additions during the quarter. JAZZ Q3 Earnings and Sales Beat Estimates
• Positive Sentiment: Analyst sentiment improved: Morgan Stanley raised its target to $319 and maintained an “overweight” rating, while RBC lifted its target to $305 with an “outperform” rating. Barclays also increased its target to $275 and retained an “overweight” rating, signaling continued confidence in Jazz’s earnings outlook. Morgan Stanley Jazz Pharmaceuticals Rating
• Positive Sentiment: Pipeline and product catalysts: Ziihera has launched in first-line HER2-positive metastatic gastric or esophageal cancer, with projected peak sales potential of $3 billion-$5 billion. Jazz also completed its Actio acquisition and plans to present neuro-oncology data, including Phase 3 ACTION trial progress, at the upcoming SNO meeting. Jazz Ziihera Revenue Guidance
• Neutral Sentiment: JAZZ was among pharmaceutical stocks showing unusually high options volume, indicating increased trading interest but not necessarily a clear directional signal. Biotech Stocks Seeing Unusual Options Volume
• Negative Sentiment: The quarter still produced a loss compared with $8.13 per share of earnings a year earlier, and commentary has raised concerns about slowing growth and charges associated with the Actio acquisition. These issues could temper the upside despite the stronger guidance. Jazz Pharmaceuticals Earnings and Guidance Analysis

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz's sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.